IPA (ImmunoPrecise Antibodies)

Highlights from JPM Healthcare 2024 🧬 It's the "Year of the Antibody" at JPM Healthcare 2024, and we're buzzing with excitement! Dr. Jennifer Bath, CEO of IPA, participated as a panelist in the sold-out discussion titled "Connecting Clusters of Excellence: Europe as Your Gateway to Global Success". Key takeaways: • Leveraging local innovation hubs effectively to create expansive global networks. • Building teams strategically with diverse experts to fuel innovation. • Belgium's favorable tax and IP policies position it as a strategic hub for life sciences. Insightful hands-on contributions from our esteemed fellow panelists Ann Belien, PhD, Youri De Groote, Robert Darwin and John Baekelmans enriched the discussion. Thank you, Health Campus Limburg DC, Yu Chen, Sara Smeets and Roeland Buckinx for organizing this impactful event. Stay connected for more updates from JPM and the forefront of healthcare innovation! Let's start the conversation on leveraging global hubs. https://bit.ly/46XqDLE #JPMHealthcare #JPM24 #Innovation #LifeSciences #GlobalNetworks #AI #ArtificialIntelligence #Antibodies #Biotechnology #healthcampuslimburgDC BioCentury Inc. Sidley Austin LLP flanders.bio Korea Biotechnology Industry Organization (KoreaBIO) Jennifer Bath, Ph.D.

2024: A Year of Transformative Progress in Biotherapeutics This year, we harnessed the power of the LENSᵃⁱ platform powered by proprietary HYFT™ pattern recognition technology and advanced simulations to tackle the most complex challenges in drug discovery. By combining innovation, collaboration, and strategic growth, we achieved milestones that are reshaping the future of biotherapeutics. ✅ Precision Oncology Breakthroughs: Leveraging HYFT-powered simulations, we developed highly specific antibodies targeting the Tumor Microenvironment (TME), advancing oncology research. ✅ LENSᵃⁱ™ Evolution: Expanded access with four models—cloud, API integrations, service offerings, and partnerships—while launching new applications like Epitope Binning & Mapping and integrating optimized tools like AlphaFold2. ✅ Key Collaborations: Partnered with BioNTech (formerly Biotheus) to engineer therapies for hypoxic tumors and InterSystems to develop Vector Search, boosting efficiency and expanding AI-powered solutions. ✅ OncoResponse Success: Rabbit anti-LILRB2 antibodies, discovered through our Rabbit B cell Select® platform, progressed to IND and Phase 1/2 trials, showing early positive clinical results in safety and efficacy. ✅ Industry Recognition: BioStrand stood out among over 1,000 applicants to win the 2024 InterSystems Impact Award, highlighting our innovative approach. ✅ Transformative Research: Collaborated with Mayo Clinic on neurodegenerative disease therapies, with findings published in Autophagy. ✅ Talem Advances: Made significant strides in TATX-112, targeting TrkB for aggressive cancers. ✅ Strategic Growth: Expanded Oss and Utrecht facilities, relocated headquarters to Austin, and hosted the first TECHday in Boston, featuring live demos of LENSᵃⁱ in action. ✅ Financial Excellence: Achieved record-breaking revenue for five consecutive quarters, capping off a landmark fiscal year. As we look to 2025, we remain committed to empowering clients with transformative solutions, seamless technology integration, and groundbreaking advancements in biotherapeutics. Together, we’re redefining what’s possible. #DrugDiscovery #Antibodies #Innovation #AI

Join IPA at the prestigious JPM 2025! IPA is excited to participate in the industry’s most prestigious global partnering platform at the J.P. Morgan Healthcare Conference, where biopharma leaders and investors connect to shape the future of healthcare innovation. 📅 January 13-16, 2025 📍 San Francisco, California Agenda: IPA and BioStrand leaders and experts—Dr. Jennifer Bath, Frederic Chabot, and Dr. Dirk Van Hyfte—will be onsite, ready to discuss how IPA's fusion of in silico, in vitro, and in vivo advanced technologies is designed to accelerate discovery timelines by up to 300%, reduce costs, and de-risk candidates for clinical success. Schedule a 1:1 meeting through the official portal: bit.ly/3BoYQtS Be sure to attend the panel discussion featuring Dr. Bath: Title: "Connecting Clusters of Excellence: Europe as your gateway to global success": Date: Monday, January 13 Time: 1:30-5:00pm Location: 555 California Street, San Francisco RSVP: bit.ly/4gJiEa9 See you in San Francisco! Let’s connect to explore collaborative strategies that maximize efficiencies, expand discovery potential, and deliver proven clinical success through partnership. #DrugDiscovery #Biotech #BioLogics #Innovation #JPM2025

Coming to you live from AET US! Our final stop of the year. 🧬 Visit booth 200 to meet Andra Li, Ph.D. and Fiona Zhang-Ruane and discover the power of the dynamic duo: IPA's proprietary Rabbit B cell Select platform with advanced in silico technologies, accelerates insights, drives innovation, and delivers breakthroughs while optimizing clinical readiness. Let’s fast-track your next discovery! Missed us at the booth - let's connect: https://lnkd.in/eTBRkN-m #AET #AntibodyDiscovery #InSilico

Join us at the Antibody Engineering & Therapeutics Conference, Dec 16-19 in San Diego. Unlock the full potential of rabbit-derived antibodies: Stop by booth #200: Discover how IPA’s strong leadership in Rabbit B cell Select® paired with advanced in silico technology delivers a >98% success rate in antibody discovery, streamlining the path to the clinic. Presentation: “Strategies to Amplify the Therapeutic Potential of Rabbit-Derived Antibodies” 📅 Dec 16 | 1:45 PM | Presentation Hall Presented by Dr. Andra Li, IPA Scientific Director Poster presentation: Amplifying the therapeutic potential of rabbit-derived antibodies by an advanced, multi-parametric humanization approach for single-step engineering. (Fusion of in vivo, in vitro and in silico technologies) Talk with the experts: Andra Li, Ph.D. and Fiona Zhang-Ruane will be available to discuss how our integrated discovery solutions can accelerate your next program. Book a meeting with us in advance through the networking app to secure a time. See you in San Diego! #Antibodies #mAb #RabbitAntibodies #Biopharma #TechBio #DrugDiscovery #AntibodyDiscovery #TherapeuticInnovation

Press Release: Strategic growth backed by financial performance. Delivers $6.1 Million Revenue for the second quarter of fiscal 2025 "This quarter marks a pivotal chapter for ImmunoPrecise Antibodies as we unveil our cutting-edge in silico drug discovery tools, designed to revolutionize the landscape of novel therapeutic development. These advanced platforms offer unprecedented insights and precision, aimed at significantly reducing the time and cost associated with traditional drug discovery methods. By harnessing the power of data-driven analytics, we're ushering in a new era of efficiency and innovation in the pharmaceutical industry. From our strategic relocation to Austin, Texas, to the continued progress with our LENSᵃⁱ™platform and partnerships with world-class organizations like BioNTech and InterSystems, we have focused on driving meaningful impact in the biotech and life sciences sectors," stated Dr. Jennifer Bath, President and CEO. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://lnkd.in/eVaabrPS. ***Participant Dial-In Details*** Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toronto (647) 932-3411 Canada - Toll-Free (800) 715-9871 ***Webcast Details*** Attendee URL: https://lnkd.in/giJ5qDvU See full release: https://lnkd.in/gyTAXnbQ #Biotech #TechBio #AI #Antibodies #DrugDiscovery

IPA to present at The Benchmark Company’s upcoming Discovery One-on-One Investor Conference Join IPA at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference on December 11, 2024, hosted at the New York Athletic Club in New York City. Jennifer Bath, Ph.D., IPA President and CEO, will lead discussions with investors and analysts, showcasing how IPA's AI-driven biotherapeutic advancements are shaping the landscape of drug discovery and development. 📅 Secure your spot: Submit your meeting requests through the event portal after registering. Register here: https://lnkd.in/gtAusumv Read the full release for more details: https://lnkd.in/gmAs2uXT Don't miss the opportunity to connect with industry-leading experts and investors focused on the future of life sciences. #TechBio #BioTech #DrugDiscovery #mAb #Antibodies Quantum Media Group, LLC Professor Ari Zoldan

Mark your calendars for the upcoming Q2 2025 earnings conference call. Join us Dec. 10, 2024, at 10:30am EST for an update on quarterly results with key insights on strategic and forward progress. Participant Dial-In Details Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toronto (647) 932-3411 Canada - Toll-Free (800) 715-9871  Webcast Details https://lnkd.in/giJ5qDvU See full release: https://lnkd.in/gSN3iu44

To those who turn challenges into solutions and ideas into breakthroughs—partners, scientists, technologists, collaborators and internal teams—we’re grateful to have you at the table with us. Together, we’re shaping a brighter future. Happy Thanksgiving to our US partners, from IPA and BioStrand (a subsidiary of IPA).

Fresh off of IPA TECHday, where the latest advancements in antibody discovery were unveiled, Dr. Jennifer Bath, IPA President and CEO, continues the conversation in an exclusive interview with Authority Magazine (Medium.com). Beyond the technology, she dives into the human element of innovation—how LENSᵃⁱ™ doesn’t just transform timelines and precision but empowers researchers to tackle complex challenges with smarter, data-driven decisions. Discover how the intersection of AI and human ingenuity is unlocking potential in biotherapeutics, accelerating breakthroughs, and reducing costs for a greater impact. Explore the full story here: https://lnkd.in/g-bVBawK #mAb #DrugDiscovery #Innovation #TechBio #AI #ArtificialIntelligence #Insilico Jennifer Bath, Ph.D.